Envestnet Asset Management Inc. Raises Stake in Edwards Lifesciences Co. (NYSE:EW)

Envestnet Asset Management Inc. increased its stake in Edwards Lifesciences Co. (NYSE:EWFree Report) by 6.9% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,241,142 shares of the medical research company’s stock after purchasing an additional 80,025 shares during the quarter. Envestnet Asset Management Inc. owned 0.20% of Edwards Lifesciences worth $94,637,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. DSM Capital Partners LLC acquired a new stake in shares of Edwards Lifesciences during the 4th quarter valued at approximately $28,000. Turtle Creek Wealth Advisors LLC purchased a new position in Edwards Lifesciences in the 4th quarter valued at approximately $34,000. Pingora Partners LLC acquired a new position in Edwards Lifesciences during the fourth quarter worth $38,000. Operose Advisors LLC boosted its position in Edwards Lifesciences by 247.0% during the third quarter. Operose Advisors LLC now owns 635 shares of the medical research company’s stock worth $44,000 after purchasing an additional 452 shares in the last quarter. Finally, SRS Capital Advisors Inc. boosted its position in Edwards Lifesciences by 292.6% during the third quarter. SRS Capital Advisors Inc. now owns 636 shares of the medical research company’s stock worth $44,000 after purchasing an additional 474 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insider Activity at Edwards Lifesciences

In other news, CEO Bernard J. Zovighian sold 8,617 shares of the stock in a transaction on Thursday, May 30th. The shares were sold at an average price of $87.68, for a total value of $755,538.56. Following the completion of the sale, the chief executive officer now owns 68,218 shares of the company’s stock, valued at $5,981,354.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In related news, VP Jean-Luc M. Lemercier sold 14,400 shares of the firm’s stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $84.21, for a total transaction of $1,212,624.00. Following the sale, the vice president now directly owns 173,849 shares in the company, valued at approximately $14,639,824.29. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Bernard J. Zovighian sold 8,617 shares of the company’s stock in a transaction that occurred on Thursday, May 30th. The stock was sold at an average price of $87.68, for a total value of $755,538.56. Following the completion of the transaction, the chief executive officer now owns 68,218 shares of the company’s stock, valued at approximately $5,981,354.24. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 136,604 shares of company stock worth $12,149,409. Company insiders own 1.27% of the company’s stock.

Edwards Lifesciences Stock Up 0.5 %

Shares of NYSE EW opened at $88.14 on Monday. The company has a quick ratio of 2.67, a current ratio of 3.75 and a debt-to-equity ratio of 0.08. The stock has a market capitalization of $53.11 billion, a PE ratio of 37.99, a P/E/G ratio of 3.22 and a beta of 1.11. The firm has a fifty day moving average of $88.35 and a 200-day moving average of $83.24. Edwards Lifesciences Co. has a 52-week low of $60.57 and a 52-week high of $96.12.

Edwards Lifesciences (NYSE:EWGet Free Report) last announced its quarterly earnings results on Thursday, April 25th. The medical research company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.64 by $0.02. The company had revenue of $1.60 billion during the quarter, compared to analyst estimates of $1.58 billion. Edwards Lifesciences had a return on equity of 22.86% and a net margin of 23.01%. On average, analysts anticipate that Edwards Lifesciences Co. will post 2.77 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. Evercore ISI cut their price target on Edwards Lifesciences from $92.00 to $89.00 and set an “in-line” rating for the company in a research note on Friday, April 26th. OTR Global raised shares of Edwards Lifesciences from a “mixed” rating to a “positive” rating in a research note on Tuesday, March 26th. Oppenheimer lifted their price objective on Edwards Lifesciences from $93.00 to $100.00 and gave the stock an “outperform” rating in a research report on Monday, March 18th. Barclays increased their target price on Edwards Lifesciences from $100.00 to $101.00 and gave the company an “overweight” rating in a report on Tuesday, May 7th. Finally, Bank of America upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating in a research report on Thursday, March 7th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and fifteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $95.06.

Read Our Latest Stock Report on EW

Edwards Lifesciences Company Profile

(Free Report)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

Recommended Stories

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Co. (NYSE:EWFree Report).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.